Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Deferred Revenue: 2010-2024

Historic Current Deferred Revenue for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $162,208.

  • China Pharma Holdings' Current Deferred Revenue rose 385.20% to $120,912 in Q3 2025 from the same period last year, while for Sep 2025 it was $120,912, marking a year-over-year increase of 385.20%. This contributed to the annual value of $162,208 for FY2024, which is 79.22% up from last year.
  • Latest data reveals that China Pharma Holdings reported Current Deferred Revenue of $162,208 as of FY2024, which was up 79.22% from $90,507 recorded in FY2023.
  • China Pharma Holdings' 5-year Current Deferred Revenue high stood at $719,786 for FY2020, and its period low was $90,507 during FY2023.
  • For the 3-year period, China Pharma Holdings' Current Deferred Revenue averaged around $257,670, with its median value being $162,208 (2024).
  • As far as peak fluctuations go, China Pharma Holdings' Current Deferred Revenue soared by 147.73% in 2022, and later slumped by 82.60% in 2023.
  • Over the past 5 years, China Pharma Holdings' Current Deferred Revenue (Yearly) stood at $719,786 in 2020, then tumbled by 70.82% to $210,028 in 2021, then soared by 147.73% to $520,295 in 2022, then crashed by 82.60% to $90,507 in 2023, then spiked by 79.22% to $162,208 in 2024.